Abbott Laboratories (ABT) Tops Q2 EPS by 1c; Raises FY11 Outlook
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $87.83 -0.66%
EPS Growth %: +1.6%
Financial Fact:
Net Sales: 5.3B
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +1.6%
Financial Fact:
Net Sales: 5.3B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q2 EPS of $1.12, $0.01 better than the analyst estimate of $1.11. Revenue for the quarter came in at $9.62 billion versus the consensus estimate of $9.56 billion.
Sees FY2011 EPS of $4.58-$4.68, versus prior guidance of $4.54-$4.64 and the consensus of $4.60.
Sees FY2011 EPS of $4.58-$4.68, versus prior guidance of $4.54-$4.64 and the consensus of $4.60.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler on Abbott Labs (ABT): 'A Name Worth Revisiting'
- Pfizer reaffirms 2026 guidance after CFO transition news
- Kroger meets earnings expectations, revenue tops estimates
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
